Deciphera Pharmaceuticals Llc Stock Number Of Shares Shorted
Deciphera Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Deciphera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Deciphera Stock. The fundamental analysis module provides a way to measure Deciphera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Deciphera Pharmaceuticals stock.
Deciphera |
Deciphera Pharmaceuticals LLC Company Number Of Shares Shorted Analysis
Deciphera Pharmaceuticals' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Deciphera Pharmaceuticals Number Of Shares Shorted | 3.92 M |
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
CompetitionBased on the recorded statements, Deciphera Pharmaceuticals LLC has 3.92 M of outstending shares currently sold short by investors. This is 22.56% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The number of shares shorted for all United States stocks is 16.67% higher than that of the company.
Deciphera Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.Deciphera Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Deciphera Fundamentals
Return On Equity | -0.5 | |||
Return On Asset | -0.27 | |||
Profit Margin | (1.09) % | |||
Operating Margin | (1.09) % | |||
Current Valuation | 1.97 B | |||
Shares Outstanding | 86.48 M | |||
Shares Owned By Insiders | 28.48 % | |||
Shares Owned By Institutions | 72.03 % | |||
Number Of Shares Shorted | 3.92 M | |||
Price To Earning | (6.78) X | |||
Price To Book | 7.00 X | |||
Price To Sales | 12.65 X | |||
Revenue | 163.36 M | |||
Gross Profit | (62.55 M) | |||
EBITDA | (210.96 M) | |||
Net Income | (194.94 M) | |||
Cash And Equivalents | 383.85 M | |||
Cash Per Share | 5.74 X | |||
Total Debt | 25.88 M | |||
Debt To Equity | 0.07 % | |||
Current Ratio | 6.02 X | |||
Book Value Per Share | 3.85 X | |||
Cash Flow From Operations | (146.7 M) | |||
Short Ratio | 1.05 X | |||
Earnings Per Share | (2.21) X | |||
Price To Earnings To Growth | (0.32) X | |||
Target Price | 27.52 | |||
Number Of Employees | 355 | |||
Beta | 0.18 | |||
Market Capitalization | 2.21 B | |||
Total Asset | 473.57 M | |||
Retained Earnings | (1.43 B) | |||
Working Capital | 280.82 M | |||
Current Asset | 70.55 M | |||
Current Liabilities | 5.98 M | |||
Net Asset | 473.57 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |